±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1693  |  »Ø¸´: 4

ZC6818418

гæ (³õÈëÎÄ̳)

[ÇóÖú] Journal of Chromatographic Science Éó¸åµÄÓйØÎÊÌâ ÒÑÓÐ1È˲ÎÓë

ÓÐÁ½¸öÎÊÌ⣺
1£¬¸ÃÔÓÖ¾µÄ²Î¿¼ÎÄÏ×ʲôҪÇó°¡£¬¸ÄÁËÁ½»ØÁË£¬¶¼²»¶Ô£¬Âé·³´ó¼Ò¿´ÏÂÄÄÀï²»·ûºÏÒªÇó¡£

Reference list
Accession numbers may be cited either within the text or in the form of a reference. The normal form of listed
references is author's surname, initials; article title; journal name in full, year in parenthesis; volume number
and inclusive page numbers.
Include titles with all journal articles. In addition, if you are citing a work listed as "In Press", please provide a
copy of that work with your submitted manuscript.
Examples£º
Journal article (already published in an issue):Vanatta, L.E., Slingsby, R.W.; United States Environmental
perchlorate Method 332.0 via microbore and capillary chromatographic formats; Journal of Chromatographic
Science, (2009); 47: 1-7.2£¬
ÎÒдµÄ²Î¿¼ÎÄÏ×£º
1. kalkman, H.O.,FUUERBACH,D.,Lotscher,E.,Schoeffter,P.,life science,(2003);1151
.U.S. FDA, Guidance for Industry: Bioanalytical Method Validation, CDER, Rockville, MD, 2001.
2. Caccia, S., Luca, P. and Nobili A.; New Atypical Antipsychotics for Schizophrenia: Iloperidone. Drug Design, Development and Therapy,(2010); 4:33-48.
3. Fairweather, D.B., Young, F. and Zaninelli, R.; Iloperidone is Effective and well Tolerated in the long Term Treatment of Schizophrenia and Schizoaffective Disorder. European Neuropsychopharmacology, (2002); 12(Supplement 3):277-278.
4. Kalkman, H.O., Feuerbach, D. Lötscher, E. and Schoeffter, P.; Functional Characterization of the Novel AntipsychoticIloperidone at Human D2,D3,a2c,5-HT6,and 5-HT1A Receptors; Life Science, (2003); 73(03):1151-1159.
5. Ichikawa, J., Li, Z., Dai, J. and Meltzer, H.Y., Atypical antipsychotic drugs, quetiapine, Iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism; Brain Res, (2002); 956: 349.
6. Kalkman, H.O., Subramanian, N. and Hoyer, D.; Extended Radioligand Binding Profile of Iloperidone: A Broad Spectrum Dopamine/Serotonin/Norepinephrine Receptor Antagonist for the Management of Psychotic Disorders; Neuropsychopharmacology, (2001); 25: 904.
7. Kalkman, H.O., Feuerbach, D., Lötscherscher, E. and Schoeffter, P.; Functional characterization of the novel antipsychotic Iloperidone at human D2, D3, ¦Á2C, 5-HT6, and 5-HT1A receptors; Life Sci, (2003); 73: 1151.
8. Kongsamut, S., Roehr, J.E., Cai, J., Hartman, H.B., Weissensee, P., Kerman, L.L., Tang, L. and Sandrasagra, A.; Iloperidone binding to human and rat dopamine and 5-HT receptors; Eur. J. Pharmacol, (1996); 317: 417.
9. Christoph, U., Todd, L. and Anil, K.; Antipsychotic Drugs and Obesity; Trends in Molecular Medicine, (2011); 17(2): 271-107.
10. Kalkman, H.O., Matkovits-Gupta, T., Alphs, L. and Gharabawi, G.; Iloperidone: A novel dopamine/serotonin antagonist with a unique preclinical profile; Eur. Neuropsychopharmacol, (1999); 9: 282.
11. Citrome, L. Meng, X.Y and Hochfeld, M.; Efficacy of Iloperidone in schizophrenia: A PANSS five-factor analysis; Schizophr. Res, (2011); 131: 75-81.
12. Crabtree, B.L. and Montgomery, J.; Iloperidone for the Management of Adults with Schizophrenia; Clin.Ther, (2011); 33: 330.
13. Sainati, S.M., Hubbard, J.W., Chi, E., Grasing, K. and Brecher, M.B.; Safety, tolerability, and effect of food on the pharmacokinetics of Iloperidone (HP 873), a potential atypical antipsychotic; J. Clin. Pharmacol, (1995); 35: 713-718.
14. Mutlib, A.E. and Strupczewski, T.; Picogram Determination of Iloperidone in Human Plasmaby solid-phase Extraction and by High-performance Liquid Chromatography-selected-ion Monitoring Electrospray Mass Spectrometry; Journal of Chromatography, (1995); 669:236-246.
15. Jia, M., Li, ., He, X.M, Liu M.Z., Zhou Y., Fan,Y., Li,W.Y., Simultaneous determination of Iloperidone and its two activemetabolites in human plasma by liquid chromatography¨Ctandem mass spectrometry: Application to a pharmacokinetic study; Journal of Chromatography B, 928 (2013) 52¨C 57.
16. Thompson, A., Chrisian, L. and Volpi, S.; Absence of Weight Gain Association with the HTR2C-759C/T Polymorphism in Patients with Schizophrenia Treated with Iloperidone; Psychiatry Research, (2010); 175:271-273.
17. Alasdair, M.B., Susan, B., Athina, M. and Mark, A.G.; Iloperidone Reduces Sensorimotor Gating Decits in Pharmacology models, but not a Developmental Model, of Disrupted Preulse Inhibition in Rats; Neuropharmacology, (2006); 51(04):457-465.
18. GEMPERLE, A.Y., ENZ, A. and POZZA, M.F.; Effects of Clozapine, Haloperidoland Iloperidone on Neurotransmission and Synaptic Prefrontal Cortex and their Accumulation in Brain Tissue: an in Vitor Study; Neuroscience, (2003); 117:681-695.
19. Citrome, L.; Iloperidone for Schizophrenia: A Review of the Efficacy and Safety Profile for this newly Commercialized Second-generation Antipsychotic; Int J Clin Pract, (2009); 63(8):1237-1248.
2£¬±¾ÎÄÐèÒªÖØ´óÐ޸ģ¬»Ø¸´Ê±µÄ¸ñʽÓÐʲôעÒâµÄô£¬ÒÔ¼°ÊÇ·ñÐèÒª¸ù¾ÝÉó¸åÒâ¼ûÒ»Ò»¶ÔÓ¦¸ø³ö´ð¸´ÄØ£¿
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

×Ô˽µÄè1988

ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
¿ªÍ·¾ÍºÃ¼¸¸ö´íÎó
1. kalkmanÊ××Öĸ´óд, H.O.,FUUERBACHÊ××Öĸ´óдÆäËû²»ÐèÒª´óд,D.,Lotscher,E.,Schoeffter,P.,life scienceÆÚ¿¯ÃûÊ××ÖĸÐèÒª´óд°É,(2003);1151
2Â¥2014-12-06 16:12:06
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ZC6818418

гæ (³õÈëÎÄ̳)

ÒýÓûØÌû:
2Â¥: Originally posted by ×Ô˽µÄè1988 at 2014-12-06 16:12:06
¿ªÍ·¾ÍºÃ¼¸¸ö´íÎó
1. kalkmanÊ××Öĸ´óд, H.O.,FUUERBACHÊ××Öĸ´óдÆäËû²»ÐèÒª´óд,D.,Lotscher,E.,Schoeffter,P.,life scienceÆÚ¿¯ÃûÊ××ÖĸÐèÒª´óд°É,(2003);1151

¸ñʽÓÐÎÊÌâô£¿»¹ÓеĶþ¸öÎÊÌâÄó¡·¡·
3Â¥2014-12-07 18:56:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ZC6818418

гæ (³õÈëÎÄ̳)

´óÉñÔÚÄÄ
4Â¥2014-12-07 18:56:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶ûÐ쳤Çä

½ð³æ (СÓÐÃûÆø)

ÇëÎÊÄúµÄJournal of Chromatographic ScienceµÄÎÄÕ±»Â¼ÁËÂð£¿Ð޸ĺó»¹Òª²»ÒªÔÙÇëר¼ÒÉó£¿Ð޸ĺó¶à¾Ã¼ÓÃÄØ£¿
5Â¥2015-11-19 10:56:59
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ZC6818418 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á +8 Mr. Z 2026-04-05 8/400 2026-04-06 09:24 by dongzh2009
[¿¼ÑÐ] Ò»Ö¾Ô¸ºÓ±±¹¤Òµ´óѧ²ÄÁϹ¤³Ì£¬³õÊÔ344Çóר˶µ÷¼Á +4 15933906766 2026-04-05 4/200 2026-04-06 07:22 by hmn_wj
[¿¼ÑÐ] »¯Ñ§0703-Ò»Ö¾Ô¸211-338·ÖÇóµ÷¼Á +8 vants 2026-04-05 8/400 2026-04-06 06:17 by houyaoxu
[¿¼ÑÐ] 294Çóµ÷¼Á +4 Grey_Ey 2026-04-01 5/250 2026-04-05 23:05 by Grey_Ey
[¿¼ÑÐ] 304Çóµ÷¼Á +3 luoye0105 2026-04-05 3/150 2026-04-05 18:16 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ0710£¨A£©³õÊÔ329·Ö Çóµ÷¼Á +4 Ò»Ãû26¿¼ÑÐÉú 2026-04-04 4/200 2026-04-05 10:01 by barlinike
[¿¼ÑÐ] µ÷¼Á +8 ÐܶþÏëÉϰ¶ 2026-04-04 8/400 2026-04-05 05:27 by houyaoxu
[¿¼ÑÐ] 320Çóµ÷¼Á +3 Ò»ÑùÔ² 2026-04-04 3/150 2026-04-04 22:29 by à£à£à£0119
[¿¼ÑÐ] 283Çóµ÷¼Á +4 mcbbc 2026-04-03 5/250 2026-04-04 20:51 by imissbao
[¿¼ÑÐ] 349Çóµ÷¼Á +11 zwjjjjjj 2026-03-31 11/550 2026-04-04 19:52 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 359Çóµ÷¼Á +7 hhhhaaaa$ 2026-04-04 7/350 2026-04-04 18:49 by imissbao
[¿¼ÑÐ] 322Çóµ÷¼Á +4 FZAC123 2026-04-03 4/200 2026-04-03 20:55 by zhq0425
[¿¼ÑÐ] »úеר˶297 +3 Afksy 2026-04-03 3/150 2026-04-03 14:24 by 1753564080
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +6 ´Þwj 2026-04-02 6/300 2026-04-03 10:19 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +6 ÏàÐűػá¹ââÍòÕ 2026-03-31 7/350 2026-04-02 23:16 by JourneyLucky
[¿¼ÑÐ] 266·Ö£¬Ò»Ö¾Ô¸µçÆø¹¤³Ì£¬±¾¿Æ²ÄÁÏ£¬Çó²ÄÁÏרҵµ÷¼Á +10 ÍÛºôºßºôºß 2026-04-01 11/550 2026-04-02 11:31 by lnilvy
[¿¼ÑÐ] Ò»Ö¾Ô¸°²»Õ´óѧ¼ÆËã»ú¿ÆÑ§Óë¼¼Êõѧ˶£¬331·ÖÇóµ÷¼Á +5 ½¯²ýÅôqtj 2026-04-01 5/250 2026-04-02 08:10 by fxue1114
[¿¼ÑÐ] »¯Ñ§¹¤³Ìר˶324·Ö£¬Ò»Ö¾Ô¸Öйú¿óÒµ´óѧÇóµ÷¼Á +7 ¹¢¹¢1314 2026-04-01 7/350 2026-04-02 07:40 by ÉÐË®¸óÖ÷
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ085601²ÄÁϹ¤³ÌÓ¢Ò»Êý¶þ³õÊÔ×Ü·Ö335Çóµ÷¼Á +5 Ë«ÂíβƦÀϰå2 2026-03-31 5/250 2026-04-01 09:04 by oooqiao
[¿¼ÑÐ] ÉúÎÑÐ337·ÖÇóµ÷¼Á +4 cgxin 2026-03-30 6/300 2026-03-31 14:18 by ¼Çʱ¾2026
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û